Evidence map›Paper›PMID 35388183›Full record

ArticleMolecular psychiatry2022

Comments to "Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists" by Khani and Entezari-Maleki.

Yaeko Hashimoto, Takuji Suzuki, Kenji Hashimoto

Abstract readLetterComment
In one paragraph

Article in Molecular psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Arketamine for cognitive impairment in psychiatric disorders.European archives of psychiatry and clinical neuroscience · 2023
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Yaeko HashimotoDepartment of Respirology, Chiba University Graduate School of Medicine, Chiba, 260-8670, Japan.
Takuji SuzukiDepartment of Respirology, Chiba University Graduate School of Medicine, Chiba, 260-8670, Japan.
Kenji HashimotoDivision of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, 260-8670, Japan. hashimoto@faculty.chiba-u.jp.ORCID http://orcid.org/0000-0002-8892-0439

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Receptors, sigmaCOVID-19 Drug TreatmentFluvoxamineHumansPost-Acute COVID-19 SyndromeSigma-1 ReceptorFluvoxamineReceptors, sigmaSigma-1 Receptor

Identifiers

PMID35388183
PMCPMC8985059

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.